Beta Bionics Inc (BBNX) Stock Price, Quote & News

Company Profile

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin with...

Industry: Medical Devices

Sector: Healthcare

Phone: 949 427 7785

Website: www.betabionics.com

Address:

11 Hughes, Irvine, United States

JFDI Jun. 28 at 11:26 PM

$BBNX mid range but on lsit

0 · Reply

ap20 Jun. 25 at 3:57 PM

$BBNX Congrats longs. No position, unfortunately.

0 · Reply

LinzonTard Jun. 20 at 10:12 PM

$PODD I’m thinking about investing in the pump/CGM space and the field is getting crowded. I think $BBNX wins with simplicity for patients and doctors. It learns dosing itself and meals are not carbohydrate counting, but easy Bolus dosing based on historical learned meals: less, same, more than usual. This will win market share.

1 · Reply

topstockalerts Jun. 4 at 10:13 PM

$BBNX the market seems reluctant to let this fade.

0 · Reply

diastud Jun. 2 at 1:14 AM

$BBNX volume is slowly increasing. This will be 2-3x soon

1 · Reply

ThePatch May. 28 at 7:50 PM

$BBNX has anyone dug into this compares to the Twiist pump?

0 · Reply

1trendingup May. 22 at 2:13 AM

$BBNX https://www.globenewswire.com/news-release/2026/05/21/3299712/0/en/beta-bionics-updates-commercialization-timeline-expectations-for-mint-its-patch-pump-in-development.html No wonder what this is up the last few days…

0 · Reply

deepthinker May. 18 at 3:32 PM

$MODD $BBNX has a patch pump coming in late 2027. I wonder if they could slap the iLet AID on Pivot, and how long that would take to get through the FDA?

1 · Reply

NVDAMillionaire May. 14 at 2:33 PM

$BBNX Really good write-up that perfectly summarizes BBNX's present situation. So if you want to bring your BBNX knowledge up to date or just discover BBNX, this is required reading. https://everyticker.com/quote/BBNX/analysis/pharmacy-channel-inflection-how-beta-bionics-is-building-a-saas-like-diabetes-franchise-nasdaq-bbnx

0 · Reply

deepthinker May. 13 at 2:18 PM

$BBNX So, they had about $200 million end of Q1. That’s about 8 quarters at current burn. So, they’ll be out of money Q1 of 2028 unless they dilute. The growth is still good, considering they have no patch pump, but I’m not clear what’s going to happen when they burn through their stash.

2 · Reply

Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026

Jun 15, 2026, 10:25 AM EDT - 19 days ago

Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)

Jun 12, 2026, 12:50 PM EDT - 22 days ago

Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth

Jun 5, 2026, 6:09 PM EDT - 4 weeks ago

Robbins LLP Reminds BBNX Stockholders of its Investigation into Beta Bionics, Inc.; Contact the Firm for Information

Jun 4, 2026, 10:18 AM EDT - 4 weeks ago

Beta Bionics, Inc. (BBNX) Investigation: Johnson Fistel Investigates Investor Losses Following Slower New Patient Start Growth

2026-06-03T20:55:26.000Z - 4 weeks ago

Beta Bionics management to meet with Piper Sandler

Jun 3, 2026, 4:09 PM EDT - 4 weeks ago

Beta Bionics, Inc. Securities Fraud Investigation – Robbins LLP is Investigating Investor Losses in BBNX Due to Possible Violations of Securities Laws

Jun 3, 2026, 9:47 AM EDT - 4 weeks ago

Beta Bionics Investors Suffer Significant Losses After Company Reports Slower New Patient Start Growth; Contact Johnson Fistel

Jun 2, 2026, 11:14 AM EDT - 4 weeks ago

Beta Bionics Investors Who Suffered Losses May Be Eligible for Recovery-Learn More Today, Contact Johnson Fistel

Jun 2, 2026, 9:00 AM EDT - 4 weeks ago

Beta Bionics First in Automated Insulin Delivery to Publish Near Real-Time Real-World Data on a Public Website

Jun 1, 2026, 6:19 PM EDT - 4 weeks ago

Robbins LLP is Investigating Allegations that the Officers and Directors of Beta Bionics, Inc. (BBNX) Violated Securities Laws and Breached Fiduciary Duties to Shareholders

Jun 1, 2026, 9:19 AM EDT - 4 weeks ago

Beta Bionics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses

2026-05-27T10:23:13.000Z - 5 weeks ago

Beta Bionics price target lowered to $17 from $19 at Goldman Sachs

2026-05-22T11:58:04.000Z - 6 weeks ago

Beta Bionics price target raised to $13 from $11 at BofA

May 21, 2026, 5:00 PM EDT - 6 weeks ago

Beta Bionics Transcript: AGM 2026

May 21, 2026, 4:04 PM EDT - 6 weeks ago

Beta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in Development

2026-05-18T12:00:44.000Z - 6 weeks ago

Beta Bionics price target lowered to $11 from $23 at BofA

May 12, 2026, 2:20 PM EDT - 7 weeks ago

Beta Bionics Transcript: Bank of America Global Healthcare Conference 2026

Apr 27, 2026, 4:25 PM EDT - 2 months ago

Beta Bionics to Present at the Bank of America Securities Health Care Conference

2026-04-22T11:50:58.000Z - 2 months ago

Beta Bionics price target lowered to $20 from $22 at Stifel

2026-04-22T11:09:16.000Z - 2 months ago

Beta Bionics price target lowered to $20 from $32 at Piper Sandler

2026-04-21T20:31:34.000Z - 2 months ago

Beta Bionics reports Q1 EPS (49c), consensus (45c)

Apr 21, 2026, 4:30 PM EDT - 2 months ago

Beta Bionics Earnings Call Transcript: Q1 2026

Apr 21, 2026, 4:30 PM EDT - 2 months ago

Beta Bionics Earnings release: Q1 2026

Apr 21, 2026, 4:30 PM EDT - 2 months ago

Beta Bionics Slides: Q1 2026

Apr 21, 2026, 4:30 PM EDT - 2 months ago

Beta Bionics Quarterly report: Q1 2026

2026-04-21T20:28:56.000Z - 2 months ago

Beta Bionics sees FY26 revenue $131M-$136M, consensus $132.58M

Apr 21, 2026, 4:03 PM EDT - 2 months ago

Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance

2026-04-15T12:36:49.000Z - 2 months ago

Beta Bionics price target lowered to $18 from $25 at Truist

Apr 14, 2026, 9:00 AM EDT - 2 months ago

Beta Bionics, Inc. Investigated by the Portnoy Law Firm

Apr 10, 2026, 8:00 AM EDT - 3 months ago

Beta Bionics Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 3 months ago

Beta Bionics Proxy statement: Proxy filing

Mar 30, 2026, 4:11 PM EDT - 3 months ago

Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026

2026-03-24T12:46:35.000Z - 3 months ago

Beta Bionics pullback an ‘overreaction,’ says Lake Street

2026-03-13T15:00:31.000Z - 4 months ago

Beta Bionics management to meet virtually with Lake Street

Mar 4, 2026, 10:30 AM EST - 4 months ago

Beta Bionics Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-24T22:20:44.000Z - 4 months ago

Beta Bionics files automatic mixed securities shelf

Feb 19, 2026, 4:05 PM EST - 4 months ago

Beta Bionics to Present at the TD Cowen 46th Annual Health Care Conference

2026-02-18T13:45:50.000Z - 4 months ago

Beta Bionics price target lowered to $20 from $40 at Lake Street

2026-02-18T12:50:59.000Z - 4 months ago

Beta Bionics price target lowered to $14 from $28 at Baird

2026-02-18T11:51:17.000Z - 4 months ago

Beta Bionics price target lowered to $22 from $25 at Stifel

2026-02-17T21:55:25.000Z - 4 months ago

Beta Bionics sees FY26 revenue $130M-$135M, consensus $132.68M

2026-02-17T21:50:27.000Z - 4 months ago

Beta Bionics reports Q4 EPS (30c), consensus (38c)

Feb 17, 2026, 4:30 PM EST - 4 months ago

Beta Bionics Earnings Call Transcript: Q4 2025

Feb 17, 2026, 4:30 PM EST - 4 months ago

Beta Bionics Annual report: Q4 2025

Feb 17, 2026, 4:30 PM EST - 4 months ago

Beta Bionics Earnings release: Q4 2025

Feb 17, 2026, 4:30 PM EST - 4 months ago

Beta Bionics Slides: Q4 2025

Feb 17, 2026, 4:05 PM EST - 4 months ago

Beta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026

2026-02-09T14:02:04.000Z - 5 months ago

Beta Bionics initiated with a Buy at UBS

Jan 21, 2026, 6:15 PM EST - 5 months ago

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Beta Bionics, Inc. (NASDAQ: BBNX)

Jan 15, 2026, 4:03 PM EST - 6 months ago

Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

Jan 15, 2026, 1:36 AM EST - 6 months ago

Beta Bionics, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - BBNX

Jan 8, 2026, 4:04 PM EST - 6 months ago

Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics

Dec 8, 2025, 7:45 AM EST - 7 months ago

Beta Bionics to Pre-Announce Topline Fourth Quarter 2025 Financial Results the Week of January 5, 2026

JFDI Jun. 28 at 11:26 PM

$BBNX mid range but on lsit

0 · Reply

ap20 Jun. 25 at 3:57 PM

$BBNX Congrats longs. No position, unfortunately.

0 · Reply

LinzonTard Jun. 20 at 10:12 PM

1 · Reply

topstockalerts Jun. 4 at 10:13 PM

$BBNX the market seems reluctant to let this fade.

0 · Reply

diastud Jun. 2 at 1:14 AM

$BBNX volume is slowly increasing. This will be 2-3x soon

1 · Reply

ThePatch May. 28 at 7:50 PM

$BBNX has anyone dug into this compares to the Twiist pump?

0 · Reply

1trendingup May. 22 at 2:13 AM

0 · Reply

deepthinker May. 18 at 3:32 PM

$MODD $BBNX has a patch pump coming in late 2027. I wonder if they could slap the iLet AID on Pivot, and how long that would take to get through the FDA?

1 · Reply

NVDAMillionaire May. 14 at 2:33 PM

0 · Reply

deepthinker May. 13 at 2:18 PM

2 · Reply

MarketBeat May. 13 at 6:06 AM

https://marketbeat.com/a/8651341/ $BBNX Beta Bionics Touts Pharmacy Push, iLet Momentum and 2027 Mint Patch Pump Plans

0 · Reply

deepthinker May. 10 at 3:18 PM

$BBNX I would be surprised if we don’t get a bid given the crushed stock price here. Easy to consolidate and clean up the SG&A. Toss the iLet in another bag. Too many players in this space.

0 · Reply

deepthinker May. 7 at 1:45 PM

$BBNX My hunch is this company could be in play here. Tandem has supply and IP issues. DEKA is private. Minimed is still owned by Medtronic.

0 · Reply

ScoutWatch12 May. 7 at 2:18 AM

$BBNX as a T1D using this pump - we aren’t wrong, just early. (It’s the same thing!! I know) patience. This is unbelievably ahead of tandem, omnipod, twist, and the unmentionables. They must figure out how to get the doctors onboard. The pump castrates the endocrinologist and they don’t like that at all.

2 · Reply

deepthinker May. 6 at 7:32 PM

$PODD Who’s likely not in play: Tandem, DEKA, MiniMed. Who’s in play: $BBNX

0 · Reply

deepthinker May. 6 at 7:01 PM

$BBNX Given Insulet’s slowing growth arc, they may look to buy growth.

0 · Reply

firewulf May. 5 at 11:39 PM

$BBNX remember when the CFO sold 30 percent of his stock at $30. Love the comments defending this company though

0 · Reply

deepthinker May. 2 at 3:42 PM

$BBNX I don’t quite understand the strategy here. They’re going to try and build revenues even if it drains cash to zero in 7 quarters? What happens then? In my opinion, there are just too many companies in this space. It’s causing spend to get out of control. The first victim will be this company. They should reverse course and go for profitability rather than growth.

4 · Reply

BillionerOfKing May. 2 at 2:30 AM

$BBNX Current Stock Price: $10.27 Contracts to trade: $10.0 BBNX May 15 2026 Call Entry: $0.55 Exit: $0.91 ROI: 66% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Arcides Apr. 28 at 7:26 PM

$BBNX medical devices stocks are trash...

1 · Reply

firewulf Apr. 27 at 4:58 PM

$BBNX 🙏

0 · Reply

PenkeInvesting Apr. 25 at 8:11 PM

Fundamental analysis of $BBNX (Beta Bionics, Inc.) based on financial data and reported results. #BBNX

0 · Reply

Market Cap	746.86M
Revenue (ttm)	100.25M
Net Income (ttm)	-73.20M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-73.02%
Debt to Equity Ratio	0.00

Volume	606,800
Avg Vol	920,426
Day's Range	N/A - N/A
Shares Out	44.56M
Stochastic %K	90%
Beta	3.04
Analysts	Strong Sell
Price Target	$19.18